Applications of coxsackievirus A21 in oncology

References

• http://www.who.int/en/[homepage on the Internet]Fact Sheet no 297, CancerWorld Health Organization2013 Available from: http://www.who.int/mediacentre/factsheets/fs297/en/Accessed February 4, 2014
   Google Scholar
• Macmillan Cancer SupportLiving After Diagnosis: Median Cancer Survival TimesLondonMacmillan Cancer Support2011 Available from: http://www.macmillan.org.uk/Documents/AboutUs/Newsroom/LivingAfterCancerMedianCancerSurvivalTimes.pdfAccessed February 4, 2014
   Google Scholar
• EagerRMNemunaitisJClinical development directions in oncolytic viral therapyCancer Gene Ther201118530531721436867
   PubMed Web of Science ®Google Scholar
• RussellSJPengKWBellJCOncolytic virotherapyNat Biotechnol201230765867022781695
   PubMed Web of Science ®Google Scholar
• PrestwichRJHarringtonKJPandhaHSVileRGMelcherAAErringtonFOncolytic viruses: a novel form of immunotherapyExpert Rev Anticancer Ther20088101581158818925850
   PubMed Web of Science ®Google Scholar
• ParatoKASengerDForsythPABellJCRecent progress in the battle between oncolytic viruses and tumoursNat Rev Cancer200551296597616294217
   PubMed Web of Science ®Google Scholar
• HuangPIChangJFKirnDHLiuTCTargeted genetic and viral therapy for advanced head and neck cancersDrug Discov Today20091411–1257057819508919
   PubMed Web of Science ®Google Scholar
• SenzerNNKaufmanHLAmatrudaTPhase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol200927345763577119884534
   PubMed Web of Science ®Google Scholar
• LiuTCGalanisEKirnDClinical trial results with oncolytic virotherapy: a century of promise, a decade of progressNat Clin Pract Oncol20074210111717259931
   PubMedGoogle Scholar
• XiaoCBator-KellyCMRiederEThe crystal structure of coxsackievirus A21 and its interaction with ICAM-1Structure20051371019103316004874
   PubMed Web of Science ®Google Scholar
• HyypiäTKallajokiMMaaronenMPathogenetic differences between coxsackie A and B virus infections in newborn miceVirus Res199327171788383395
   PubMed Web of Science ®Google Scholar
• NewcombeNGBeagleyLGChristiansenDNovel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivityJ Virol20047822126771268215507656
   PubMed Web of Science ®Google Scholar
• AuGGBeagleyLGHaleyESBarryRDShafrenDROncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18Virol J201182221241513
   PubMed Web of Science ®Google Scholar
• ShafrenDRDorahyDJInghamRABurnsGFBarryRDCoxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entryJ Virol1997716473647439151867
   PubMed Web of Science ®Google Scholar
• HopkinsAMBairdAWNusratAICAM-1: targeted docking for exogenous as well as endogenous ligandsAdv Drug Deliv Rev200456676377815063588
   PubMed Web of Science ®Google Scholar
• JohanssonESXingLChengRHShafrenDREnhanced cellular receptor usage by a bioselected variant of coxsackievirus a21J Virol20047822126031261215507647
   PubMed Web of Science ®Google Scholar
• BjørgeLJensenTSMatreRCharacterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell lineCancer Immunol Immunother19964231851928640847
   PubMed Web of Science ®Google Scholar
• RegidorPACalliesRRegidorMSchindlerAEExpression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding seraEur J Gynaecol Oncol19981943773839744730
   PubMed Web of Science ®Google Scholar
• KageshitaTYoshiiAKimuraTClinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanomaCancer Res19935320492749328104688
   PubMed Web of Science ®Google Scholar
• KomiJLassilaOToremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cellsScand J Immunol2000511737810632979
   PubMed Web of Science ®Google Scholar
• MurrayKPMathureSKaulRExpression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissueGynecol Oncol200076217618210637067
   PubMed Web of Science ®Google Scholar
• JohnsonJPStadeBGHolzmannBSchwäbleWRiethmüllerGDe novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasisProc Natl Acad Sci U S A19898626416442643120
   PubMed Web of Science ®Google Scholar
• MieleMEBennettCFMillerBEWelchDREnhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotidesExp Cell Res199421412312417915992
   PubMed Web of Science ®Google Scholar
• JohnsonJPStadeBGHupkeUHolzmannBRiethmüllerGThe melanoma progression-associated antigen P3.58 is identical to the intercellular adhesion molecule, ICAM-1Immunobiology198817832752843229781
   PubMed Web of Science ®Google Scholar
• AuGGLinczLFEnnoAShafrenDROncolytic Coxsackievirus A21 as a novel therapy for multiple myelomaBr J Haematol2007137213314117391493
   PubMed Web of Science ®Google Scholar
• ShafrenDRAuGGNguyenTSystemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21Clin Cancer Res2004101 Pt 1536014734451
   PubMed Web of Science ®Google Scholar
• AuGGLindbergAMBarryRDShafrenDROncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21Int J Oncol20052661471147615870858
   PubMed Web of Science ®Google Scholar
• Viralytics: Investigator information [webpage on the Internet]. http://www.viralytics.com/clinical-trial-information/investigator-informationAccessed February 13, 2014
   Google Scholar
• HadacEMRussellSJ436. Coxsackievirus A21 has potent oncolytic activity in multiple myeloma [Abstract]Mol Ther200613Suppl 1S168
   Web of Science ®Google Scholar
• RosetteCRothRBOethPRole of ICAM1 in invasion of human breast cancer cellsCarcinogenesis200526594395015774488
   PubMed Web of Science ®Google Scholar
• SkeldingKABarryRDShafrenDRSystemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21Breast Cancer Res Treat20091131213018256929
   PubMed Web of Science ®Google Scholar
• RokhlinOWCohenMBExpression of cellular adhesion molecules on human prostate tumor cell linesProstate19952642052127536326
   PubMed Web of Science ®Google Scholar
• LiuAYRoudierMPTrueLDHeterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profileAm J Pathol200416551543155615509525
   PubMed Web of Science ®Google Scholar
• BerryLJAuGGBarryRDShafrenDRPotent oncolytic activity of human enteroviruses against human prostate cancerProstate200868657758718288643
   PubMed Web of Science ®Google Scholar
• YeeYWVChanSHQuahMYShafrenDAuGOncolytic activity of coxsackievirus A21 (CAVATAK) in human lung cancer: a novel targeted anti-cancer strategyPoster presented at: 14th World Conference on Lung CancerJuly 3–7, 2011Amsterdam, the Netherlands
   Google Scholar
• PatelMRKratzkeRAOncolytic virus therapy for cancer: the first wave of translational clinical trialsTransl Res2013161435536423313629
   PubMed Web of Science ®Google Scholar
• ScherRLKochWMRichtsmeierWJInduction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gammaArch Otolaryngol Head Neck Surg199311944324388096142
   PubMedGoogle Scholar
• SauthoffHHuJMacaCIntratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time pointsHum Gene Ther200314542543312691608
   PubMed Web of Science ®Google Scholar
• HammillAMConnerJCripeTPOncolytic virotherapy reaches adolescencePediatr Blood Cancer20105571253126320734404
   PubMed Web of Science ®Google Scholar
• PrestwichRJIlettEJErringtonFImmune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replicationClin Cancer Res200915134374438119509134
   PubMed Web of Science ®Google Scholar
• PrestwichRJErringtonFSteeleLPReciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirusJ Immunol200918374312432119734207
   PubMed Web of Science ®Google Scholar
• HadacEMKellyEJRussellSJMyeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acidMol Ther20111961041104721505425
   PubMed Web of Science ®Google Scholar
• AdairRARoulstoneVScottKJCell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsSci Transl Med20124138138ra77
   Web of Science ®Google Scholar
• LiHZengZFuXZhangXCoadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responsesCancer Res200767167850785517699791
   PubMed Web of Science ®Google Scholar
• UngerechtsGSpringfeldCFrenzkeMEAn immunocompetent murine model for oncolysis with an armed and targeted measles virusMol Ther200715111991199717712331
   PubMed Web of Science ®Google Scholar
• QiaoJWangHKottkeTCyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirusClin Caner Res2008141259269
   PubMed Web of Science ®Google Scholar
• ThomasMASpencerJFTothKSagartzJEPhillipsNJWoldWSImmunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster modelMol Ther200816101665167318665155
   PubMed Web of Science ®Google Scholar
• KanervaANokisalmiPDiaconuIAntiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirusClin Cancer Res201319102734274423493351
   PubMed Web of Science ®Google Scholar
• PowerATWangJFallsTJCarrier cell-based delivery of an oncolytic virus circumvents antiviral immunityMol Ther200715112313017164783
   PubMed Web of Science ®Google Scholar
• FisherKDStallwoodYGreenNKUlbrichKMautnerVSeymourLWPolymer-coated adenovirus permits efficient retargeting and evades neutralising antibodiesGene Ther20018534134811313809
   PubMed Web of Science ®Google Scholar
• GreenNKHerbertCWHaleSJExtended plasma circulation time and decreased toxicity of polymer-coated adenovirusGene Ther200411161256126315215884
   PubMed Web of Science ®Google Scholar
• RussellSJPengKWViruses as anticancer drugsTrends Pharmacol Sci200728732633317573126
   PubMed Web of Science ®Google Scholar
• TsengJCGranotTDiGiacomoVLevinBMerueloDEnhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumorCancer Gene Ther201017424425519798121
   PubMed Web of Science ®Google Scholar
• LiauwWSChernBShafrenDRPhase I, Open-Label, Cohort Study of CAVATAK (Coxsackievirus A21), Given Intravenously to Stage IV Patients Bearing ICAM-1 Expressing Solid TumoursPoster presented at: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics6–9 November 2012Dublin, Ireland
   Google Scholar
• ReidTWarrenRKirnDIntravascular adenoviral agents in cancer patients: lessons from clinical trialsCancer Gene Ther200291297998612522437
   PubMed Web of Science ®Google Scholar
• KellyEJHadacEMGreinerSRussellSJEngineering microRNA responsiveness to decrease virus pathogenicityNat Med200814111278128318953352
   PubMed Web of Science ®Google Scholar
• SkeldingKABarryRDShafrenDREnhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochlorideInvest New Drugs201230256858121170760
   PubMed Web of Science ®Google Scholar
• SimpsonGRAjazMLaunchburyFAMajor synergy between Coxsackievirus A21 (CAVATAK™) and radiotherapy or chemotherapy in bladder cancer cell lines, due to up-regulation viral receptors ICAM-1 and DAFPoster presented at: Seventh International Meeting on Replicating Oncolytic Virus TherapeuticsJune 15–18, 2013Quebec, Canada Available from: http://www.viralytics.com/media/presentations/130618%20ONCO%20Meeting%20CAVATAK%20and%20Bladder%20Cancer%20Pandha.pdf
   Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar